GLOBAL Sarcoma Therapy Now Approved for Australian Patients

Globally regarded soft tissue sarcoma therapy has been approved by the Therapeutic Goods Administration for Australian patients YONDELISÒ (trabectedin) demonstrates 45% reduction in risk of disease progression or death versus dacarbazine1 SING... Biopharmaceuticals, Oncology, Regulatory Specialised Therapeutics Asia, YONDELIS, trabectedin, liposarcoma, leiomyosarcom
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news